Synsorb Biotech Inc.

SYNSORB Biotech Inc. is a publicly traded Canadian pharmaceutical company dedicated to drug development and manufacturing. The Company has two late-stage products, both of which are based on SYNSORB’s proprietary carbohydrate chemistry platform technology, and both of which have been granted “Fast Track Designation” from the USFDA. Headquartered in Calgary, SYNSORB currently has two such carbohydrate products in late stage clinical development, SYNSORB Pk® and SYNSORB Cd®. SYNSORB Pk® is in Phase III clinical trials and is designed to prevent the progression to Hemolytic Uremic Syndrome (HUS) in children who have contracted verotoxigenic E. coli (VTEC) infections (including E. coli O157:H7). SYNSORB Cd® is designed to treat recurrent Clostridium difficile antibiotic-associated diarrhea (CDAD), a common hospital acquired infection. Phase III trials began in April 2000 at sites in Canada, the USA, Peurto Rico and Mexico. In addition to SYNSORB Pk® and SYNSORB Cd®, the Company is also involved in the development of the reovirus through its subsidiary, Oncolytics Biotech Inc. as well as a powerful new drug screening method through its subsidiary, INH Technologies Incorporated. Future products that the Company is developing in its R & D program include potential treatments arising from the carbohybrid libraries. (Products available for licensing)

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: